These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 11014248)

  • 1. 17beta-estradiol, but not raloxifene, decreases thrombomodulin in the antithrombotic protein C pathway.
    Richardson MA; Berg DT; Calnek DS; Ciaccia AV; Joyce DE; Grinnell BW
    Endocrinology; 2000 Oct; 141(10):3908-11. PubMed ID: 11014248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of endothelial nitric-oxide synthase phosphorylation by the raloxifene analog LY117018 is differentially mediated by Akt and extracellular signal-regulated protein kinase in vascular endothelial cells.
    Hisamoto K; Ohmichi M; Kanda Y; Adachi K; Nishio Y; Hayakawa J; Mabuchi S; Takahashi K; Tasaka K; Miyamoto Y; Taniguchi N; Murata Y
    J Biol Chem; 2001 Dec; 276(50):47642-9. PubMed ID: 11595733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Raloxifene acutely stimulates nitric oxide release from human endothelial cells via an activation of endothelial nitric oxide synthase.
    Simoncini T; Genazzani AR
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2966-9. PubMed ID: 10946913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective estrogen receptor modulators: different actions on vascular cell adhesion molecule-1 (VCAM-1) expression in human endothelial cells.
    Simoncini T; De Caterina R; Genazzani AR
    J Clin Endocrinol Metab; 1999 Feb; 84(2):815-8. PubMed ID: 10022460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with raloxifene and 17beta-estradiol differentially modulates nitric oxide and prostanoids in venous endothelium and platelets of ovariectomized pigs.
    Lewis DA; Avsar M; Labreche P; Bracamonte M; Jayachandran M; Miller VM
    J Cardiovasc Pharmacol; 2006 Nov; 48(5):231-8. PubMed ID: 17110805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective estrogen receptor modulators prevent neointima formation after vascular injury.
    Savolainen-Peltonen H; Luoto NM; Kangas L; Häyry P
    Mol Cell Endocrinol; 2004 Nov; 227(1-2):9-20. PubMed ID: 15501580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of selective estrogen receptor modulator/raloxifene analogue on proliferation and collagen metabolism of tendon fibroblast.
    Irie T; Takahata M; Majima T; Abe Y; Komatsu M; Iwasaki N; Minami A
    Connect Tissue Res; 2010 Jun; 51(3):179-87. PubMed ID: 20073985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of raloxifene, a selective estrogen receptor modulator, on thymus, T cell reactivity, and inflammation in mice.
    Erlandsson MC; Gömöri E; Taube M; Carlsten H
    Cell Immunol; 2000 Nov; 205(2):103-9. PubMed ID: 11104582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different effects of raloxifene and estrogen on interleukin-1beta and interleukin-1 receptor antagonist production using in vitro and ex vivo studies.
    Rogers A; Clowes JA; Pereda CA; Eastell R
    Bone; 2007 Jan; 40(1):105-10. PubMed ID: 16934544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Raloxifene analog LY 117018 effects on central and peripheral beta-endorphin.
    Genazzani AR; Bernardi F; Stomati M; Rubino S; Giardina L; Luisi S; Monteleone P; Genazzani AD; Luisi M; Petraglia F
    Gynecol Endocrinol; 1999 Aug; 13(4):249-58. PubMed ID: 10533160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Raloxifene plus 17beta-estradiol inhibits proliferation of primary cultured vascular smooth muscle cells and human mammary endothelial cells via the janus kinase/signal transducer and activator of transcription3 cascade.
    Wang TH; Xiang QL; Chen JW; Pan H; Cui YH
    Eur J Pharmacol; 2007 Apr; 561(1-3):7-13. PubMed ID: 17336289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-inflammatory effect of selective estrogen receptor modulators (SERMs) in microglial cells.
    Suuronen T; Nuutinen T; Huuskonen J; Ojala J; Thornell A; Salminen A
    Inflamm Res; 2005 May; 54(5):194-203. PubMed ID: 15953991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cardiovascular effects of selective estrogen receptor modulators.
    Christodoulakos GE; Lambrinoudaki IV; Botsis DC
    Ann N Y Acad Sci; 2006 Dec; 1092():374-84. PubMed ID: 17308162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo activation of gene transcription via oestrogen response elements by a raloxifene analogue.
    Engdahl C; Jochems C; Gustafsson JA; van der Saag PT; Carlsten H; Lagerquist MK
    J Endocrinol; 2009 Dec; 203(3):349-56. PubMed ID: 19752149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombin downregulates thrombomodulin expression and activity in primary human endothelial cells.
    Séguin C; Abid MR; Spokes KC; Aird WC
    Endothelium; 2008; 15(3):143-8. PubMed ID: 18568955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic concentrations of raloxifene augment nitric oxide-dependent coronary artery dilatation in vitro.
    Leung FP; Yung LM; Leung HS; Au CL; Yao X; Vanhoutte PM; Laher I; Huang Y
    Br J Pharmacol; 2007 Sep; 152(2):223-9. PubMed ID: 17618301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Raloxifene modulates estrogen-mediated B cell autoreactivity in NZB/W F1 mice.
    Zhang Y; Saha S; Rosenfeld G; Gonzalez J; Pepeljugoski KP; Peeva E
    J Rheumatol; 2010 Aug; 37(8):1646-57. PubMed ID: 20551107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of estrogen agonism and antagonism of tamoxifen, raloxifene, and ICI182780 in endometrial cancer cells: a putative role for the epidermal growth factor receptor ligand amphiregulin.
    Gielen SC; Burger CW; Kühne LC; Hanifi-Moghaddam P; Blok LJ
    J Soc Gynecol Investig; 2005 Oct; 12(7):e55-67. PubMed ID: 16202921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquired protein C dysfunction but not decreased activity of thrombomodulin is a possible marker of thrombophilia in patients with lupus anticoagulant.
    Pötzsch B; Kawamura H; Preissner KT; Schmidt M; Seelig C; Müller-Berghaus G
    J Lab Clin Med; 1995 Jan; 125(1):56-65. PubMed ID: 7822946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of selective oestrogen receptor modulators (SERMs) tamoxifen, ospemifene and raloxifene on human osteoclasts in vitro.
    Michael H; Härkönen PL; Kangas L; Väänänen HK; Hentunen TA
    Br J Pharmacol; 2007 Jun; 151(3):384-95. PubMed ID: 17420779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.